Register entry
- Registered sites
- 13
- Active NDC listings
- 130
- Labeller names
- 3
- Live patents
- 460
- Exclusivities
- 10
- Shortage listings
- 17
- Countries
- 5
- Base
- United States
Authorisation
Registered operations
Analytical testing12Active ingredient (API) manufacture7Labelling4Finished drug manufacture10Packaging4
Sites
Registered establishments
13| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| AbbVie Biotechnology GmbHRegistrant: AbbVie Inc. | Knollstr., Ludwigshafen, 67061, Germany (DEU) | Analytical testing | 3011277200332980213 |
| AbbVie Deutschland GmbH & Co KGRegistrant: AbbVie Inc. | Knollstrasse, Ludwigshafen, - 67061, Germany (DEU) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3002807401342730478 |
| Fournier Laboratories Ireland LimitedRegistrant: AbbVie Inc. | IDA Industrial Estate, CARRIGTWOHILL, - T45 K202, Ireland (IRL) | Analytical testing, Finished drug manufacture | 3004134577989881180 |
| AbbVie Ireland NL B.V.Registrant: AbbVie Inc. | Manorhamilton Road, Sligo, Co Sligo -, Ireland (IRL) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3004364014985098845 |
| AbbVie Ireland NL. B.V.Registrant: AbbVie Inc. | AbbVie Biologics Ballytivnan Road, Sligo, F91 K735, Ireland (IRL) | Finished drug manufacture | 3012441529986062732 |
| AbbVie SRLRegistrant: AbbVie Inc. | Strada Regionale 148 Pontina KM.52, Campoverde di Aprilia, Latina 04011, Italy (ITA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3002806277430395311 |
| AbbVie Operations Singapore Pte. Ltd.Registrant: AbbVie Inc. | 23 Tuas South Avenue 6, Singapore, Singapore 637022, Singapore (SGP) | Analytical testing, Active ingredient (API) manufacture | 3011774256595396775 |
| AbbVie Biotechnology LTDRegistrant: AbbVie Inc. | Road NO 2 KM 59.2, Barceloneta, Puerto Rico (PR) 00617, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3004620772078521681 |
| AbbVie LtdRegistrant: AbbVie Inc. | State Road No 2 Km 58 Cruce Davila, Barceloneta, Puerto Rico (PR) 00617, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3000210838078521897 |
| AbbVie Inc. | 1401 Sheridan Road, North Chicago, Illinois (IL) 60064, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 1411365078521674 |
| AbbVie Inc. | 1 N Waukegan Rd, North Chicago, Illinois (IL) 60064, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3009751352078458370 |
| AbbVie Bioresearch CenterRegistrant: AbbVie Inc. | 100 Research Drive, Worcester, Massachusetts (MA) 01605, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3003684386078521730 |
| AbbVie Inc. | 1609 Biddle Ave, LT4 Plant, Bldg 63, Wyandotte, Michigan (MI) 48192, United States (USA) | Analytical testing, Active ingredient (API) manufacture | 3010166391078521672 |
Alert
Drug shortage listings
17| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Lopinavir and Ritonavir Oral SolutionAntiviral | Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Lopinavir and Ritonavir TabletAntiviral | Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Lopinavir and Ritonavir TabletAntiviral | Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Lopinavir and Ritonavir TabletAntiviral | Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Lopinavir and Ritonavir TabletAntiviral | Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Ritonavir Oral PowderAntiviral | Norvir, Oral Powder, 100 mg (NDC 0074-3399-30) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Ritonavir TabletAntiviral | Norvir, Tablet, 100 mg (NDC 0074-2340-30) | To Be Discontinued | - | 24 Jul 202624 Jul 2026 |
| Nitroglycerin OintmentAnalgesia/Addiction | Rectiv, Ointment, 0.4% (NDC 58914-301-80) | To Be Discontinued | - | 14 Apr 202614 Apr 2026 |
| Progesterone Vaginal GelUrology | Crinone, Vaginal Gel, 4% (NDC 0023-6150-04) | To Be Discontinued | - | 27 Mar 202627 Mar 2026 |
| Pilocarpine Hydrochloride Ophthalmic SolutionOphthalmology | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03) | To Be Discontinued | - | 24 Mar 202624 Mar 2026 |
| Pilocarpine Hydrochloride Ophthalmic SolutionOphthalmology | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04) | To Be Discontinued | - | 24 Mar 202624 Mar 2026 |
| Pilocarpine Hydrochloride Ophthalmic SolutionOphthalmology | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05) | To Be Discontinued | - | 24 Mar 202624 Mar 2026 |
| Pilocarpine Hydrochloride Ophthalmic SolutionOphthalmology | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01) | To Be Discontinued | - | 24 Mar 202624 Mar 2026 |
| Pilocarpine Hydrochloride Ophthalmic SolutionOphthalmology | Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06) | To Be Discontinued | - | 24 Mar 202624 Mar 2026 |
| Podofilox Topical GelDermatology, Other | Condylox , Topical Gel, 0.5% (NDC 0023-6118-03) | To Be Discontinued | - | 28 Jan 202628 Jan 2026 |
| Paricalcitol CapsuleEndocrinology/Metabolism | Zemplar, Capsule, 1 ug (NDC 0074-9036-30) | To Be Discontinued | - | 7 Oct 20257 Oct 2025 |
| Paricalcitol CapsuleEndocrinology/Metabolism | Zemplar, Capsule, 2 ug (NDC 0074-9037-30) | To Be Discontinued | - | 7 Oct 20257 Oct 2025 |
Catalogue
Drug listings by form and route
130130 active NDC listings: 94 human prescription drug, 26 drug for further processing, 10 bulk ingredient. By marketing category: NDA 59, BLA 33, DRUG FOR FURTHER PROCESSING 25, BULK INGREDIENT 10, ANDA 2.
| Dosage form | NDCs |
|---|---|
| kit | 27 |
| tablet | 23 |
| tablet, film coated | 13 |
| injection, solution | 11 |
| capsule, delayed release pellets | 8 |
| liquid | 7 |
| powder | 7 |
| capsule | 6 |
| injection | 6 |
| tablet, extended release | 6 |
| injection, powder, lyophilized, for solution | 3 |
| tablet, delayed release | 3 |
| capsule, delayed release | 2 |
| capsule, liquid filled | 2 |
| solution | 2 |
| Route | NDCs |
|---|---|
| oral | 51 |
| intravenous | 9 |
| subcutaneous | 6 |
| endotracheal | 1 |
| enteral | 1 |
| respiratory (inhalation) | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| abbvie inc. | 126 |
| abbvie srl | 3 |
| abbvie biotechnology ltd | 1 |
Exclusivity
Patents and exclusivities
460| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7741358*PED | SAPHRISasenapine maleate | use | Oct 2026 |
| 8022228*PED | SAPHRISasenapine maleate | use | Oct 2026 |
| 7612087 | AVYCAZ, EMBLAVEOavibactam sodium; aztreonam; avibactam sodium; ceftazidime | product | Nov 2026 |
| 10441543 | DURYSTAbimatoprost | product | Dec 2026 |
| 9149428 | DURYSTAbimatoprost | product | Dec 2026 |
| 7304036*PED | LINZESSlinaclotide | use | Feb 2027 |
| 10617695 | LASTACAFTalcaftadine | product | Mar 2027 |
| 8206737 | DURYSTAbimatoprost | use | Apr 2027 |
| 8008338 | ACULAR LSketorolac tromethamine | substance, product | May 2027 |
| 7851504 | LUMIGANbimatoprost | substance, product | Jun 2027 |
| 7838552 | BYVALSONnebivolol hydrochloride; valsartan | use | Oct 2027 |
| 8008338*PED | ACULAR LSketorolac tromethamine | use | Nov 2027 |
| 7622130 | KYBELLAdeoxycholic acid | use | Dec 2027 |
| 7754230 | KYBELLAdeoxycholic acid | use | Dec 2027 |
| 8664215 | LASTACAFTalcaftadine | use | Dec 2027 |
| 8461140 | KYBELLAdeoxycholic acid | product | Feb 2028 |
| 8546367 | KYBELLAdeoxycholic acid | product | Feb 2028 |
| 8883770 | KYBELLAdeoxycholic acid | product | Feb 2028 |
| 9522155 | KYBELLAdeoxycholic acid | product | Feb 2028 |
| 9636349 | KYBELLAdeoxycholic acid | use | Feb 2028 |
| 9949986 | KYBELLAdeoxycholic acid | use | Feb 2028 |
| 8512717 | ACUVAILketorolac tromethamine | product | Mar 2028 |
| 9192571 | ACUVAILketorolac tromethamine | product | Mar 2028 |
| 8242294 | KYBELLAdeoxycholic acid | substance | May 2028 |
| 6900175 | DALVANCEdalbavancin hydrochloride | use | May 2028 |
| 8217083 | CANASAmesalamine | product | Jun 2028 |
| 8436051 | CANASAmesalamine | product | Jun 2028 |
| 8691860 | VIBERZIeluxadoline | substance | Jul 2028 |
| 9115091 | VIBERZIeluxadoline | substance, product | Jul 2028 |
| 9364489 | VIBERZIeluxadoline | use | Jul 2028 |
| 9789125 | VIBERZIeluxadoline | product | Jul 2028 |
| 8501238 | VIEKIRA PAK (COPACKAGED), VIEKIRA XRdasabuvir sodium; ombitasvir, paritaprevir, ritonavir; dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | substance, product | Sept 2028 |
| 11459305 | ORIAHNN (COPACKAGED)elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | product | Nov 2028 |
| 9139536 | VIEKIRA PAK (COPACKAGED), VIEKIRA XRdasabuvir sodium; ombitasvir, paritaprevir, ritonavir; dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | use | Nov 2028 |
| 7943621 | VRAYLARcariprazine hydrochloride | substance, product | Dec 2028 |
| 8039009 | NAMENDA XR, NAMZARICdonepezil hydrochloride; memantine hydrochloride; memantine hydrochloride | use | Mar 2029 |
| 7799336 | DURYSTAbimatoprost | product | Apr 2029 |
| 8188104 | VIEKIRA PAK (COPACKAGED), VIEKIRA XRdasabuvir sodium; ombitasvir, paritaprevir, ritonavir; dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | substance, product | May 2029 |
| 7741356 | VIBERZIeluxadoline | substance, product | May 2029 |
| 7943621*PED | VRAYLARcariprazine hydrochloride | use | Jun 2029 |
| 7419983 | ORIAHNN (COPACKAGED), ORILISSAelagolix sodium; elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | substance, product | Jul 2029 |
| RE47350 | VRAYLARcariprazine hydrochloride | use | Jul 2029 |
| RE49110 | VRAYLARcariprazine hydrochloride | use | Jul 2029 |
| RE49302 | VRAYLARcariprazine hydrochloride | use | Jul 2029 |
| 7842714 | ACUVAILketorolac tromethamine | substance, product | Aug 2029 |
| 8642538 | TECHNIVIE, VIEKIRA PAK (COPACKAGED), VIEKIRA XRdasabuvir sodium; ombitasvir, paritaprevir, ritonavir; dasabuvir sodium; ombitasvir; paritaprevir; ritonavir; ombitasvir; paritaprevir; ritonavir | substance, product | Sept 2029 |
| 7737142 | VRAYLARcariprazine hydrochloride | substance, product | Sept 2029 |
| 7994220 | SAVELLAmilnacipran hydrochloride | use | Sept 2029 |
| 8039009*PED | NAMENDA XR, NAMZARICdonepezil hydrochloride; memantine hydrochloride; memantine hydrochloride | use | Sept 2029 |
| 10449173 | GELNIQUEoxybutynin chloride | product | Nov 2029 |
| 9259388 | GELNIQUEoxybutynin chloride | use | Nov 2029 |
| 8058291 | NAMZARICdonepezil hydrochloride; memantine hydrochloride | use | Dec 2029 |
| RE47350*PED | VRAYLARcariprazine hydrochloride | use | Jan 2030 |
| RE49110*PED | VRAYLARcariprazine hydrochloride | use | Jan 2030 |
| RE49302*PED | VRAYLARcariprazine hydrochloride | use | Jan 2030 |
| 10500214 | KYBELLAdeoxycholic acid | product | Mar 2030 |
| 8101593 | KYBELLAdeoxycholic acid | product | Mar 2030 |
| 8367649 | KYBELLAdeoxycholic acid | product | Mar 2030 |
| 8653058 | KYBELLAdeoxycholic acid | product | Mar 2030 |
| 7737142*PED | VRAYLARcariprazine hydrochloride | use | Mar 2030 |
| Product | Exclusivity | Until |
|---|---|---|
| AVYCAZAVIBACTAM SODIUM; CEFTAZIDIME | NPP New patient population | Jan 2027 |
| EMBLAVEOAVIBACTAM SODIUM; AZTREONAM | GAIN Qualified infectious disease product (GAIN) | Feb 2033 |
| LINZESSLINACLOTIDE | NPP New patient population | May 2029 |
| LINZESSLINACLOTIDE | PED Paediatric | May 2029 |
| MAVYRETGLECAPREVIR; PIBRENTASVIR | PED Paediatric | Dec 2028 |
| RINVOQUPADACITINIB | ODE-481 Orphan drug | Apr 2031 |
| RINVOQUPADACITINIB | ODE-538 Orphan drug | Apr 2032 |
| RINVOQ LQUPADACITINIB | ODE-481 Orphan drug | Apr 2031 |
| VRAYLARCARIPRAZINE HYDROCHLORIDE | PED Paediatric | Jun 2029 |
| VYALEVFOSCARBIDOPA; FOSLEVODOPA | NP New product | Oct 2027 |
Catalogue
Marketed products
131Showing 130 of 131.
| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Adalimumab | liquid | 0074-1867BULK INGREDIENT |
| Creon | Pancrelipase | capsule, delayed release, oral | 0032-0045BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-0046BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-0047BLA |
| Creon | Pancrelipase | capsule, delayed release, oral | 0032-1203BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-1206BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-1212BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-1224BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-2636BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-2637BLA |
| Creon | Pancrelipase | capsule, delayed release pellets, oral | 0032-3016BLA |
| - | Cyclosporine | powder | 0074-5503BULK INGREDIENT |
| DECNUPAZ | pivekimab sunirine-pvzy | injection, powder, lyophilized, for solution, intravenous | 0074-0282BLA |
| Depakote | Divalproex Sodium | tablet, delayed release, oral | 0074-7325NDA |
| Depakote | Divalproex Sodium | tablet, delayed release, oral | 0074-7326NDA |
| Depakote | Divalproex Sodium | tablet, delayed release, oral | 0074-7327NDA |
| Depakote ER | Divalproex Sodium | tablet, extended release, oral | 0074-7401NDA |
| Depakote ER | Divalproex Sodium | tablet, extended release, oral | 0074-7402NDA |
| Depakote Sprinkles | Divalproex Sodium | capsule, oral | 0074-6114NDA |
| Duopa | Carbidopa and Levodopa | suspension, enteral | 0074-3012NDA |
| EMBLAVEO | aztreonam and avibactam | powder, for solution, intravenous | 0074-3878NDA |
| EMRELIS | Telisotuzumab Vedotin | injection, powder, lyophilized, for solution, intravenous | 0074-1044BLA |
| EMRELIS | Telisotuzumab Vedotin | injection, powder, lyophilized, for solution, intravenous | 0074-1055BLA |
| - | Elagolix Sodium | powder | 0051-0040BULK INGREDIENT |
| - | Foscarbidopa | powder | 62526-1737BULK INGREDIENT |
| - | Foslevodopa | powder | 62526-1912BULK INGREDIENT |
| Gengraf | Cyclosporine | capsule, oral | 0074-3108ANDA |
| Gengraf | Cyclosporine | capsule, oral | 0074-3109ANDA |
| Humira | Adalimumab | kit | 0074-0124BLA |
| Humira | Adalimumab | kit | 0074-0243BLA |
| Humira | Adalimumab | kit | 0074-0554BLA |
| Humira | Adalimumab | kit | 0074-0616BLA |
| Humira | Adalimumab | kit | 0074-0817BLA |
| Humira | Adalimumab | kit | 0074-1539BLA |
| Humira | Adalimumab | kit | 0074-2540BLA |
| Humira | Adalimumab | kit | 0074-3799BLA |
| Humira | Adalimumab | kit | 0074-4339BLA |
| - | IBRUTINIB | tablet | 0074-2585DRUG FOR FURTHER PROCESSING |
| - | Ibrutinib | capsule | 0074-0070DRUG FOR FURTHER PROCESSING |
| - | Ibrutinib | capsule | 0074-2628DRUG FOR FURTHER PROCESSING |
| Kaletra | Lopinavir and Ritonavir | tablet, film coated, oral | 0074-3008NDA |
| Kaletra | Lopinavir and Ritonavir | solution, oral | 0074-3956NDA |
| Kaletra | Lopinavir and Ritonavir | tablet, film coated, oral | 0074-4014NDA |
| Lupron Depot | leuprolide acetate | kit | 0074-3346NDA |
| Lupron Depot | leuprolide acetate | kit | 0074-3473NDA |
| Lupron Depot | leuprolide acetate | kit | 0074-3641NDA |
| Lupron Depot | leuprolide acetate | kit | 0074-3642NDA |
| Lupron Depot | leuprolide acetate | kit | 0074-3663NDA |
| Lupron Depot | leuprolide acetate | kit | 0074-3683NDA |
| Lupron Depot-PED | leuprolide acetate | kit | 0074-2108NDA |
| Lupron Depot-PED | leuprolide acetate | kit | 0074-2282NDA |
| Lupron Depot-PED | leuprolide acetate | kit | 0074-2440NDA |
| Lupron Depot-PED | leuprolide acetate | kit | 0074-3575NDA |
| Lupron Depot-PED | leuprolide acetate | kit | 0074-3779NDA |
| Lupron Depot-PED | leuprolide acetate | kit | 0074-9694NDA |
| Mavyret | Glecaprevir and Pibrentasvir | pellet, oral | 0074-2600NDA |
| Mavyret | Glecaprevir and Pibrentasvir | tablet, film coated, oral | 0074-2625NDA |
| Norvir | Ritonavir | tablet, film coated, oral | 0074-2340NDA |
| Norvir | Ritonavir | powder, oral | 0074-3399NDA |
| - | Olaparib | tablet, film coated | 0074-0668DRUG FOR FURTHER PROCESSING |
| - | Olaparib | tablet, film coated | 0074-0679DRUG FOR FURTHER PROCESSING |
| Oriahnn | Elagolix and Estradiol and Norethisterone | kit | 0074-1017NDA |
| Orilissa | Elagolix | tablet, film coated, oral | 0074-0038NDA |
| Orilissa | Elagolix | tablet, film coated, oral | 0074-0039NDA |
| Qulipta | Atogepant | tablet, oral | 0074-7094NDA |
| Qulipta | Atogepant | tablet, oral | 0074-7095NDA |
| Qulipta | Atogepant | tablet, oral | 0074-7096NDA |
| - | RISANKIZUMAB | injection, solution | 0074-1058DRUG FOR FURTHER PROCESSING |
| Rinvoq | Upadacitinib | tablet, extended release, oral | 0074-1043NDA |
| Rinvoq | Upadacitinib | tablet, extended release, oral | 0074-2306NDA |
| Rinvoq | Upadacitinib | tablet, extended release, oral | 0074-2310NDA |
| Rinvoq | Upadacitinib | solution, oral | 0074-2320NDA |
| - | Risankizumab | liquid | 0074-1059BULK INGREDIENT |
| - | Risankizumab | liquid | 0074-1078BULK INGREDIENT |
| - | Risankizumab | injection, solution | 0074-5016DRUG FOR FURTHER PROCESSING |
| - | Risankizumab | injection, solution | 0074-5025DRUG FOR FURTHER PROCESSING |
| - | Risankizumab | injection, solution | 0074-9000DRUG FOR FURTHER PROCESSING |
| - | Risankizumab | injection, solution | 0074-9010DRUG FOR FURTHER PROCESSING |
| - | Risankizumab | liquid | 0074-9011DRUG FOR FURTHER PROCESSING |
| - | SOTATERCEPT | liquid | 0074-2242BULK INGREDIENT |
| Skyrizi | risankizumab-rzaa | injection, subcutaneous | 0074-1050BLA |
| Skyrizi | Risankizumab-rzaa | kit, intravenous | 0074-1065BLA |
| Skyrizi | Risankizumab-rzaa | kit, intravenous | 0074-1070BLA |
| Skyrizi | risankizumab-rzaa | injection, subcutaneous | 0074-2100BLA |
| Skyrizi | risankizumab-rzaa | injection, solution, subcutaneous | 0074-4059BLA |
| Skyrizi | risankizumab-rzaa | injection, intravenous | 0074-5015BLA |
| Skyrizi | Risankizumab-rzaa | kit | 0074-7040BLA |
| Skyrizi | Risankizumab-rzaa | kit | 0074-7042BLA |
| Skyrizi | risankizumab-rzaa | injection, subcutaneous | 0074-8300BLA |
| Skyrizi | risankizumab-rzaa | injection, subcutaneous | 0074-8350BLA |
| Survanta | Beractant | suspension, endotracheal | 0074-1040BLA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-3727NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-4341NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-4552NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-5182NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-6594NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-6624NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-7068NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-7069NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-7070NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-7148NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-7149NDA |
| Synthroid | Levothyroxine Sodium | tablet, oral | 0074-9296NDA |
| Ultane | Sevoflurane | liquid, respiratory (inhalation) | 0074-4456NDA |
| - | Upadacitinib | tablet | 0074-2241DRUG FOR FURTHER PROCESSING |
| - | Upadacitinib | tablet, extended release | 0074-2250DRUG FOR FURTHER PROCESSING |
| - | Upadacitinib | powder | 62526-2325BULK INGREDIENT |
| - | Valproate Semisodium | capsule | 0074-0805EXPORT ONLY |
| - | Vedolizumab | liquid | 0051-2638BULK INGREDIENT |
| Venclexta | Venetoclax | tablet, film coated, oral | 0074-0561NDA |
| Venclexta | Venetoclax | tablet, film coated, oral | 0074-0566NDA |
| Venclexta | Venetoclax | tablet, film coated, oral | 0074-0576NDA |
| Venclexta | Venetoclax | kit | 0074-0579NDA |
| - | Venetoclax | powder | 0074-0598DRUG FOR FURTHER PROCESSING |
| - | Venetoclax | tablet | 76462-0576DRUG FOR FURTHER PROCESSING |
| Vyalev | foscarbidopa/foslevodopa | injection, subcutaneous | 0074-0501NDA |
| Zemplar | Paricalcitol | injection, solution, intravenous | 0074-1658NDA |
| Zemplar | Paricalcitol | injection, solution, intravenous | 0074-4637NDA |
| Zemplar | Paricalcitol | capsule, liquid filled, oral | 0074-9036NDA |
| Zemplar | Paricalcitol | capsule, liquid filled, oral | 0074-9037NDA |
| - | adalimumab | injection, solution | 0074-1115DRUG FOR FURTHER PROCESSING |
| - | adalimumab | injection, solution | 0074-1117DRUG FOR FURTHER PROCESSING |
| - | adalimumab | injection, solution | 0074-2330DRUG FOR FURTHER PROCESSING |
| - | atogepant | tablet | 0074-7091DRUG FOR FURTHER PROCESSING |
| - | atogepant | tablet | 0074-7092DRUG FOR FURTHER PROCESSING |
| - | atogepant | tablet | 0074-7093DRUG FOR FURTHER PROCESSING |
| - | ubrogepant | tablet | 0074-6501DRUG FOR FURTHER PROCESSING |
| - | upadacitinib | tablet | 0074-2309DRUG FOR FURTHER PROCESSING |
| - | venetoclax | tablet, film coated | 0074-1087DRUG FOR FURTHER PROCESSING |
| - | venetoclax | tablet, film coated | 0074-1137DRUG FOR FURTHER PROCESSING |
Neighbours
Registered in the same town
12- Merck & Co., Inc.Singapore, SGP · 5 sites
- SanofiSingapore, SGP · 2 sites
- Novartis Pharmaceuticals CorporationSingapore, SGP
- Viatris Inc.Barceloneta, PR
- Baxalta US Inc.Singapore, SGP
- Charles River Laboratories, Inc.Singapore, SGP
- Lonza Biologics IncSingapore, SGP
- Pfizer IncSingapore, SGP
- The Procter & Gamble Manufacturing CompanyNorth Chicago, IL
- Amgen, IncSingapore, SGP
- Genentech, Inc.Singapore, SGP
- Almac Pharma Services (Ireland) LimitedSingapore, SGP
Compare
Comparable companies in United States
- Sigma-Aldrich Corporation13 sites · 25 NDC
- Siegfried USA, LLC12 sites · 54 NDC
- SOFIE Co. dba SOFIE12 sites · 5 NDC
- The Procter & Gamble Manufacturing Company11 sites · 849 NDC
- AstraZeneca PLC15 sites · 153 NDC
- Lonza Biologics Inc15 sites · 80 NDC
- Zoetis Inc11 sites · 29 NDC
- Pfizer Inc11 sites · 27 NDC
- Oxarc LLC15 sites · 5 NDC
- Sotera Health LLC11 sites · 2 NDC
Enquiry
Common questions
- Is AbbVie Inc. FDA approved?
- AbbVie Inc. holds 13 FDA-registered establishments across 5 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are AbbVie Inc.'s drugs manufactured?
- At registered sites in Germany, Ireland, Italy, Singapore, the United States. The FDA register lists Ludwigshafen; CARRIGTWOHILL; Sligo; Campoverde di Aprilia; Singapore; Barceloneta, PR, and 3 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does AbbVie Inc. make?
- 131 products are listed under AbbVie Inc. in the openFDA NDC Directory, most often as kit; tablet; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.